Clinical Trials Logo

Delirium clinical trials

View clinical trials related to Delirium.

Filter by:

NCT ID: NCT06421090 Recruiting - Clinical trials for Vagus Nerve Stimulation

Transauricular Vagal Nerve Stimulation Improves Postoperative Delirium in Elderly Patients

Vnstar-IIa
Start date: May 21, 2024
Phase: N/A
Study type: Interventional

To investigate the efficacy and safety of perioperative Transauricular vagal nerve stimulation in improving Postoperative Delirium in elderly patients undergoing elective surgery Lay the groundwork for a Phase III study.

NCT ID: NCT06421077 Recruiting - Clinical trials for Vagus Nerve Stimulation

Transauricular Vagus Nerve Stimulation Improves Postoperative Delirium in Elderly Patients

Vnstar
Start date: May 21, 2024
Phase: N/A
Study type: Interventional

According to the 3D-CAM scale, evaluate the incidence of Postoperative Delirium within 5 days after surgery in elderly patients receiving Transauricular vagal nerve stimulation.The results are expected to provide evidence of the safety and efficacy of perioperative prophylactic use of taVNS in the clinical application of improving postoperative brain health in elderly patients, as well as theoretical and practical basis for subsequent studies or clinical applications.

NCT ID: NCT06411561 Not yet recruiting - Dementia Clinical Trials

A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit Survivors

SLEEP-COG
Start date: July 1, 2024
Phase: N/A
Study type: Interventional

Up to 25% of intensive care unit (ICU) survivors experience cognitive impairment comparable in severity to mild Alzheimer's disease and related dementias after hospital discharge. Older ICU survivors (ages 60 and older) are at highest risk for delirium and subsequent cognitive impairment, which contribute to higher risk for cognitive decline related to Alzheimer's disease and related dementias. Sleep and activity are essential for recovery from critical illness, yet ICU survivors experience both sleep deficiency and profound inactivity. About 75-80% of ICU patients experience circadian dysrhythmia, which contributes to cognitive decline and increases likelihood of developing Alzheimer's disease and related dementias. The scientific premises of the proposed study are: 1) a combined sleep promotion and cognitive training intervention will have synergistic effects to mitigate the risk of cognitive impairment and development of Alzheimer's disease and related dementias in older ICU survivors; and 2) chronotherapeutic timing of interventions (i.e., adjusting timing of interventions according to circadian rhythm) may improve intervention efficacy.

NCT ID: NCT06406257 Not yet recruiting - Emergence Delirium Clinical Trials

Temperature Management on Postoperative Delirium

POD
Start date: May 20, 2024
Phase: N/A
Study type: Interventional

Presently, the effects of perioperative temperature management on postoperative delirium remain ambiguous. This study endeavors to explore the influence of intraoperative temperature variations in elderly hip fracture patients on postoperative delirium.

NCT ID: NCT06403410 Not yet recruiting - Delirium Clinical Trials

Delirium Prevention Guideline for Intensive Care Patients

Start date: June 15, 2024
Phase: N/A
Study type: Interventional

Delirium is a complication characterized by fluctuations in orientation, memory, thinking, or behavior, with sudden onset of these changes. Studies have shown that pharmacological agents are the most significant risk factors for delirium in intensive care units. In recent years, the impact of non-pharmacological interventions in preventing delirium development has started to be discussed.

NCT ID: NCT06400706 Not yet recruiting - Postoperative Pain Clinical Trials

Effect of Electroencephalography Guided General Anesthesia on Postoperative Delirium in Children

Start date: May 15, 2024
Phase: N/A
Study type: Interventional

Participants aged 4-10 years (92 patients), who came to the Hospital Operating Room at the University Faculty of Dentistry with an indication for dental treatment under general anesthesia due to lack of cooperation, will be selected by simple randomization and divided into 2 groups. One group of participants who will undergo routine general anesthesia and dental treatment procedures will receive routine monitoring (Group I), and the other group will receive EEG monitoring (Group II) in addition to routine monitoring. Electrocardiography (ECG), oxygen saturation (SpO2), non-invasive blood pressure (NIBP), endtidal carbon dioxide (EtCO2), endtidal sevoflurane (EtSev) parameters observed as routine monitoring of the patients will be recorded and the minimal alveolar concentration (MAC) value will be kept at 0.9. Anesthesia management will be performed, and in Group II, in addition to routine monitoring, anesthesia management will be carried out to keep the SEF values observed in the EEG between 10-15 and PSI values between 25-50. Routine general anesthesia procedures and dental treatments will not differ between groups. Age, gender, weight, intubation type, ASA, previous surgical experience, anesthesia duration, number of extracted teeth with decayed fillings (dmft) values will also be recorded. In the intraoperative period; hemodynamic parameters (average heart rate, blood pressure and oxygen saturation values) and amounts of medication consumed (most tidal sevoflurane percentages in induction and maintenance, presence of burst suppression, sevoflurane/fentanyl/rocuronium consumption). The participants, whose operation is completed, will be taken to the recovery room and any post-operative discomfort will be noted. The cases will be recorded in the report form. In the postoperative period; Extubation time, agitation (PAED scores) and pain (FLACC, VAS-ORF) scores will be recorded during extubation and 10, 20, 30 minutes and 2 hours after extubation, and recovery time, hospital stay, presence of nausea and vomiting will also be recorded. Modified Aldrete Recovery Score (MAS) will be used for recovery criteria and MAS >8 will be considered as a recovery indicator. The Pediatric Anesthesia Early Delirium Scale (PAED) will be used to evaluate early agitation. FLACC and VAS-ORF scale will be used as pain scales.

NCT ID: NCT06399679 Not yet recruiting - Clinical trials for Anticholinergic Toxicity

Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium

RIVA-AP
Start date: June 2024
Phase: Phase 2
Study type: Interventional

Antimuscarinic delirium (AMD) is a common and dangerous toxicology condition caused by poisoning by medications and other chemicals that block muscarinic receptors. Physostigmine is effective in reversing AMD but has a short duration of action, and patient commonly experience recurrence of AMD after initial control with physostigmine. Recent case reports and small observational studies suggest that rivastigmine, which has a longer duration of action than physostigmine, might be useful in the treatment of AMD. In order to investigate the effectiveness of rivastigmine in preventing recurrence of AMD after initial control with physostigmine, the investigators propose a randomized, placebo-controlled clinical trial of rivastigmine for AMD. The investigators hypothesize that patients treated with rivastigmine after initial control of AMD with physostigmine will experience less recurrence of antimuscarinic delirium than those treated with placebo.

NCT ID: NCT06398275 Recruiting - Emergence Delirium Clinical Trials

Remimazolam for Emergence Delirium Prevention in Patients Undergoing Rhinoseptoplasty, FESS or Septoplasty

Start date: March 6, 2024
Phase: Phase 2
Study type: Interventional

The aim of this research is to confirm the effectiveness of remimazolam in preventing delirium during recovery from anesthesia in adult patients who have undergone one of the rhinological surgeries (septoplasty, rhinoseptoplasty or functional endoscopic sinus surgery). Patients aged 18-65, ASA classification I-II will be anesthetized with balanced anesthesia maintained with sevoflurane and will be randomized into two groups. The first group will receive remimazolam before anesthesia, while the second will receive normal saline solution. The main outcome of the study will be the presence/absence of delirium during anesthesia recovery, while the secondary outcome will be the postoperative pain level, the length of stay in the recovery room, the presence of unwanted events in the recovery room, and the presence of postoperative mood changes.

NCT ID: NCT06396468 Recruiting - Emergence Delirium Clinical Trials

Sevoflurane and Intravenous Anesthesia in Hypospadias Repair

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

Emergence agitation (EA), a phenomenon observed at the time of recovery from general anesthesia (GA).The cause of ED appears to be multifactorial in origin. Use of volatile anesthetics, prolonged duration and type of surgery, pain, and rapid emergence are some factors known to increase its incidence

NCT ID: NCT06394778 Not yet recruiting - Delirium Clinical Trials

Electroencephalogram Characteristics of Surgical Anesthetized Patients and Postoperative. Dilirium

Start date: April 22, 2024
Phase:
Study type: Observational

Purpose:Construct a perioperative EEG database for elderly patients under general anesthesia, and explore the correlation between their EEG spectrum characteristics and the occurrence and severity of postoperative delirium. Content:This study aims to investigate patients undergoing elective orthopedic surgery, analyze the changes in perioperative EEG spectrum, correlate with the occurrence and severity of POD, and explore the relationship between perioperative EEG changes and the development of postoperative delirium. Method: Patients aged over 60 years old who are scheduled for orthopedic surgery and plan to stay in hospital for more than two days were selected. All patients underwent preoperative MMSE and 3D-CAM assessments. Subsequently, anesthetic depth monitor electrodes were applied to the occipital or frontal-temporal regions of the patient to collect electroencephalograms of the occipital lobe during conscious and quiet states, the frontal lobe during general anesthesia, and the recovery room. During PACU, scores were calculated based on the CAM-ICU scale evaluation. During the first 5 days after surgery, patients were evaluated every day between 13:00 and 20:00 using 3D-CAM, or at any time when they showed obvious symptoms of delirium, unless they were discharged or taking sedatives (RASS < -3). Ten minutes after the end of the evaluation, patients' electroencephalograms were monitored in a conscious and quiet state, or in a state of obvious delirium. Patients were divided into a delirium group and a non-delirium group based on whether they developed delirium after surgery. The characteristics of electroencephalograms before, during, and after surgery were analyzed in both groups of patients.Research significance:The results of this study may provide objective indicators and theoretical basis for monitoring and diagnosing the occurrence and development of POD, which can help clinical doctors identify patients with increased delirium risk in the early stage, and adjust the plan in a timely manner to change the triggering risk factors of POD.